

FACULTY DISCLOSURE INFORMATION



Symposium ADC's Toxicities: Optimizing Patient Management and Outcomes February 2, 2023

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "**ineligible company**" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
Speaker/Moderators			
Robert Coleman, MD	Planning/Speaker		Agenus; Alkermes, Inc.; AstraZeneca; Clovis Oncology, Inc.; Deciphera Pharmaceuticals Inc.; EISAI INC.; Genentech USA, Inc.; GlaxoSmithKline; Gradalis; Mersana; Novocure Inc.; oncxerna; Regeneron Pharmaceuticals: Consultant Abbvie; Immunogen; Janssen Biotech, Inc.; Merck; Novartis; Onxeo; Seagen Inc.: Grant / Contract Vbl: Data And Safety Monitoring
Ramez Eskander, MD	Planning/Speaker		Advisory Board/Consulting Fee/Speaking: AstraZeneca; Merck; Clovis; GSK, Myriad
Megan Berkenstock, MD	Planning/Speaker		EyePoint Pharmaceuticals: Consultant
R. Wendel Naumann, MD	Planning/Speaker		Merck Sharp & Dohme; AstraZeneca; Clovis Oncology; OncoMed; Eisai; Bristol-Myers Squibb; Seattle Genetics; Agenus; Sutro Biopharma; GOG Partners; GlaxoSmithKline/Tesaro; Genelix; Laekna Therapeutics: Consultant Seattle Genetics: Speakers Bureau Bristol-Myers Squibb; OncoMed; Sutro Biopharma; Gynecologic Oncology Group; Mersana; GlaxoSmithKline/Tesaro: Research Funding
Angeles Alvarez Secord, MD	Planning/Speaker		AbbVie; Aravive; AstraZeneca; Clovis Oncology, Inc.; Eisai; Genentech; GSK; Merck; National Cancer Trial Network; Oncoquest; Seagen Inc; Tapimmune; VBL Therapeutics: Grant / Contract Immunogen; Myriad Genetic Laboratories, Inc.: Consultant AAOGF; GOG Foundation; SGO: Other
Michelle Small	Staff	X	
Jill Reese	Staff	X	